Bodart V, Babinski K, Ong H, De Léan A
Department of Pharmacology, Faculty of Medicine, Université de Montréal, Québec, Canada.
Endocrinology. 1997 Feb;138(2):566-73. doi: 10.1210/endo.138.2.4915.
The purpose of this study was to investigate the mechanisms of action of pituitary adenylate cyclase-activating polypeptide (PACAP) in stimulating aldosterone production in two different models: bovine adrenal zona glomerulosa (ZG) cells in primary culture and the human adrenocortical carcinoma cell line H295R. PACAP binds to two major groups of receptors: type I, which prefers PACAP38 and PACAP27 over vasoactive intestinal peptide (VIP); and type II, which has approximately equal affinity for PACAP38, PACAP27, and VIP. The type I subclass comprises multiple splice variants that can be distinguished by their specificity to PACAP38 and PACAP27 in their activation of adenylate cyclase and phospholipase C. Type II PACAP/ VIP receptors couple only to AC. In bovine ZG cells, PACAP38 and PACAP27 stimulated aldosterone production in a dose-dependent manner, whereas VIP was ineffective. In H295R cells, PACAP38, PACAP27, and VIP dose-dependently stimulated aldosterone production with roughly the same ED50. In bovine ZG cells, PACAP38 and PACAP27 stimulated cAMP production with similar efficacy, whereas VIP had no effect. In H295R cells, all three peptides stimulated cAMP accumulation. PACAP38 and PACAP27 also activated PLC in bovine ZG cells as they induced an increase in Ins(1,4,5)Ps production. In H295R cells, neither of these peptides was able to stimulate IP turnover. These results indicate that PACAP stimulation of aldosterone production is mediated by the PVR1s or the PVR1hop splice variants of the type I PACAP-specific receptor subtype in bovine ZG cells, whereas only type II PACAP/VIP receptors seemed to occur in the human H295R cell line. In addition, PACAP-stimulated aldosterone production was inhibited by atrial natriuretic peptide in bovine and human adrenocortical cells, however not by the same mechanism. This further supports species-specific and/or cell type-specific signaling pathways for PACAP in the regulation of aldosterone production.
本研究的目的是在两种不同模型中研究垂体腺苷酸环化酶激活多肽(PACAP)刺激醛固酮生成的作用机制:原代培养的牛肾上腺球状带(ZG)细胞和人肾上腺皮质癌细胞系H295R。PACAP与两大类受体结合:I型受体,相较于血管活性肠肽(VIP),其更倾向于结合PACAP38和PACAP27;II型受体,对PACAP38、PACAP27和VIP具有大致相同的亲和力。I型亚类包含多种剪接变体,可通过它们在激活腺苷酸环化酶和磷脂酶C时对PACAP38和PACAP27的特异性来区分。II型PACAP/VIP受体仅与AC偶联。在牛ZG细胞中,PACAP38和PACAP27以剂量依赖性方式刺激醛固酮生成,而VIP无效。在H295R细胞中,PACAP38、PACAP27和VIP以大致相同的半数有效剂量(ED50)剂量依赖性地刺激醛固酮生成。在牛ZG细胞中,PACAP38和PACAP27以相似的效力刺激cAMP生成,而VIP无作用。在H295R细胞中,所有三种肽均刺激cAMP积累。PACAP38和PACAP27还激活牛ZG细胞中的PLC,因为它们诱导Ins(1,4,5)Ps生成增加。在H295R细胞中,这两种肽均不能刺激IP周转。这些结果表明,在牛ZG细胞中,PACAP刺激醛固酮生成是由I型PACAP特异性受体亚型的PVR1s或PVR1hop剪接变体介导的,而在人H295R细胞系中似乎仅存在II型PACAP/VIP受体。此外,在牛和人肾上腺皮质细胞中,心房利钠肽抑制PACAP刺激的醛固酮生成,但作用机制不同。这进一步支持了PACAP在调节醛固酮生成中存在物种特异性和/或细胞类型特异性信号通路。